NEC in Preemies: Gut Inflammation Linked to Lasting Brain Injury

A severe gut disease in premature infants, necrotizing enterocolitis (NEC), does more than damage the intestines—it fundamentally alters brain development, leaving up to 40% of survivors with lasting cognitive, motor, and behavioral impairments. A comprehensive new review led by Augusto Zani, with colleagues Michele Bosisio and Miguel A. Garcia from the Division of Surgery at Washington University in St Louis, synthesizes decades of clinical data and emerging molecular evidence to show that NEC itself drives brain injury through a powerful inflammatory cascade originating in the gut. The study was published (DOI: 10.1136/wjps-2026-001199) in the World Journal of Pediatric Surgery on July 13, 2026.

The review highlights that the severity of intestinal disease is a primary driver of neurodevelopmental impairment (NDI). Surgically treated infants, who have more extensive bowel necrosis, consistently show higher rates of cerebral palsy, lower IQ scores, and greater cognitive deficits than those managed medically. Neuroimaging confirms reduced brain volume, delayed cortical folding, and white matter injury correlating with intestinal inflammation. This damage appears mediated by a breakdown of the blood-brain barrier, allowing gut-derived immune cells and inflammatory proteins to infiltrate the brain. Specifically, high-mobility group box 1 (HMGB1), released from dying gut cells, is identified as a critical driver. Preclinical studies show that blocking HMGB1-Toll-like receptor 4 (TLR4) signaling or preventing immune cell infiltration can reduce injury in animal models. Emerging risk factors like hyponatremia and thrombocytopenia are highlighted as potential early warning signs, underscoring the importance of rapid surgical intervention.

The authors emphasize that this inflammation-driven process may be treatable, with the HMGB1–TLR4 axis being a promising target. They call for structured, long-term neurodevelopmental follow-up for all NEC survivors and suggest that clinical decisions, such as timing of surgery, have profound neurological implications. The mechanistic findings open the door for clinical trials of novel therapies, including antioxidants like N-acetylcysteine, human milk oligosaccharides, or HMGB1 inhibitors like glycyrrhizin. Ultimately, the study shifts the paradigm from simply treating the gut to protecting the brain, paving the way for a dual-pronged clinical approach that aims to save both the intestines and the mind.